Who is sponsoring NCT06023173?

NCT06023173 is sponsored by Fudan University.

What drugs are being tested in NCT06023173?

Interventions in NCT06023173: Deep radiomics-based fusion model.

What condition does NCT06023173 study?

NCT06023173 studies The Patients With CRLM Who Benefit More From Bevacizumab.

Is NCT06023173 still recruiting?

NCT06023173 is currently completed. Last updated 14 September 2023.

Last reviewed 2023-09-14 · How we verify

NCT06023173

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases

Completed Last updated 14 September 2023

What this trial tests

trial testing Deep radiomics-based fusion model in The Patients With CRLM Who Benefit More From Bevacizumab in 307 participants. Completed in 1 January 2023.

Timeline

1 October 2013

Primary endpoint
1 January 2023

1 January 2023

Quick facts

Lead sponsor	Fudan University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	307
Start date	1 October 2013
Primary completion	1 January 2023
Estimated completion	1 January 2023
Sites	1 location across China

Drugs / interventions tested

Deep radiomics-based fusion model

Conditions studied

The Patients With CRLM Who Benefit More From Bevacizumab — all drugs for The Patients With CRLM Who Benefit More From Bevacizumab →

Sponsor

Fudan University

Who can join

Adults 18 to 75, any sex, with The Patients With CRLM Who Benefit More From Bevacizumab. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multi-modal deep radiomics model, using PET/CT, clinical and histopathological data, was able to identify patients with bevacizumab-sensitive unresectable colorectal cancer liver metastases, providing a favorable approach for precise patient treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Artificial Intelligence Applications in the Treatment of Colorectal Cancer: A Narrative Review.
Yang J, Huang J, Han D, Ma X. · · 2024 · cited 10× · PMID 38187459 · DOI 10.1177/11795549231220320

Verify or expand the search:

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06023173 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 14 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06023173.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing